Adepend (Naltrexone) is used in the therapeutic domain of addiction recovery and contributes to support for individuals managing Substance Use Disorders. This medication is commonly used across conditions presenting with episodic or fluctuating symptom patterns. Its therapeutic focus is on Opioid Use Disorder (OUD) and Alcohol Use Disorder (AUD).

The primary benefit is centered on easing the disruptive symptom of intense craving associated with both substances. This contribution helps to address symptom clusters that may become intense or disruptive, assisting with maintaining functional stability during challenging periods.

“This medication is considered relevant in contexts marked by increased discomfort or tension related to compulsive substance use.”

QuickFact: Supportive Relief for Cravings and Relapse Risk

Adepend is commonly used to help with the maintenance of sobriety following detoxification from opioids and may assist patients who are working towards the therapeutic goals of reduced heavy drinking or complete abstinence in AUD. It provides support that helps ease the overall symptom burden, particularly during phases of increased distress or discomfort related to cravings.

Who Can and Cannot Use Adepend?

Eligibility for Adepend (naltrexone hydrochloride) is strictly defined by regulatory authorities and centers on the patient's opioid status, organ function, and age.

---

Contraindications and Restrictions

Classification	Who Must Not Use (Contraindicated)
Opioid Status	Patients who are currently opioid-dependent, in acute opioid withdrawal, or actively using opioid analgesics.
Organ Function	Individuals with acute hepatitis, liver failure, or severe renal impairment.
Hypersensitivity	Patients with known hypersensitivity to naltrexone hydrochloride or its excipients.

---

Population-Specific Limitations

Adepend is primarily indicated for use in adults who are confirmed to be opioid-free. It is not recommended for children and adolescents (under 18 years) because regulatory bodies state that safe use has not been established due to insufficient data. Similarly, data on safe use in the elderly for opiate dependence are insufficient.

For patients with slight or moderate liver or kidney disorder, the medicine is restricted and requires special caution and close supervision. Regarding pregnancy, use is conditional and only advised when potential benefits outweigh the possible risks; breastfeeding is not recommended as naltrexone passes into breast milk.

Adepend Interactions with other medicines and products

Interaction scope

Classification	Documentation Statement
Opioid Analgesics	Contraindicated: Co-administration with any opioid-containing medicinal product is formally prohibited due to the risk of precipitating acute withdrawal or reversing analgesic effect [FDA Labeling; EMA SmPC].
Opioid-Containing Medicines	Restriction: This prohibition extends to opioid-based anti-diarrheal agents and cough/cold preparations containing opioids [EMA SmPC].
CNS Depressants	Caution: Lethargy and somnolence have been reported following co-administration with Thioridazine [FDA Labeling].
Hepatotoxic Agents	Caution: Increased risk of liver injury is noted when administered with other potentially hepatotoxic agents, particularly in populations with impaired hepatic function [NIH DailyMed].

Interaction structure and metabolism

Adepend (Naltrexone) interaction profile is defined by its core action of opioid antagonism, which results in the absolute constraint against concurrent use with all opioid substances. Official regulatory sources state that neither naltrexone nor its active metabolite is significantly metabolized by human Cytochrome P450 (CYP) enzymes, indicating the primary interaction constraints are pharmacodynamic, rather than metabolic. No mandatory timing rules are documented requiring dose separation from non-opioid co-administered drugs. No direct pharmacokinetic interaction with alcohol is explicitly documented in labeling.

How Adepend Works

Adepend's mechanism of action is defined by its selective, competitive interaction with the opioid receptor system, resulting in the interruption of typical opioid signaling.

---

Antagonism of the Mu-Opioid Receptor (MOR)

The primary action of Adepend (Naltrexone Hydrochloride) is its high-affinity, competitive binding to the Mu-opioid receptor (μ-OR). It functions as a pure antagonist, meaning it occupies the receptor site but does not activate it, thereby functionally neutralizing the impact of both administered opioids and the body's endogenous opioid peptides. This molecular blockade is sustained by the action of its potent metabolite, 6-beta-naltrexol, contributing to the sustained duration of the pathway interruption.

---

Modulation of the Central Reward Circuitry

This receptor blockade leads directly to the modulation of the mesolimbic dopamine pathway in the central nervous system (CNS). By preventing the typical downstream disinhibition cascade in regions like the Nucleus Accumbens, Naltrexone modulates the surge of dopamine associated with opioid activity. This mechanistic intervention produces the physiological effect of attenuating the reinforcement signal within the brain's reward system.

How Adepend is Used: Official Administration Guidelines

Adepend (naltrexone hydrochloride) is an oral medication administered as a 50 mg film-coated tablet, which is the only approved form for this product. The tablets are scored, enabling division for the 25 mg initial dose required during treatment induction for opioid dependence.

---

Standard Dosing Structure

For adult patients, the standard daily dose is 50 mg, taken once daily. To support adherence, an alternative schedule is approved, consisting of 100 mg on Monday and Wednesday, and 150 mg on Friday, totaling 350 mg per week. Instructions caution against administering doses over 150 mg in a single day. If a dose is missed, the patient should resume taking the 50 mg tablet daily until the next scheduled dose.

---

Administration Context and Course Duration

Treatment must be initiated and overseen by suitably qualified physicians. For Opioid Use Disorder, a critical requirement is that the patient must be confirmed opioid-free for a minimum of 7 to 10 days before the first dose. This is commonly verified using a urine screen or a Naloxone challenge test. The tablets should be swallowed with liquid, and administration may occur under fasting conditions.

The course of use typically begins with a minimum period of three months of administration, with the understanding that prolonged use may be necessary based on individual patient needs. Use is not recommended in patients under 18 years of age.

Research Evidence / Overview of Studies for Adepend

This overview summarizes the research evidence and study landscape for oral Naltrexone (Adepend), focusing strictly on information found in authoritative governmental and peer-reviewed scientific sources.

Evidence from Randomized Controlled Trials (RCTs) for Alcohol Use Disorder (AUD)

Research examined Naltrexone in individuals with Alcohol Use Disorder (AUD) primarily through large-scale Randomized Controlled Trials (RCTs). Studies monitored responses in populations that were often also receiving psychosocial support. Research examined outcomes related to alcohol consumption patterns, such as the frequency of heavy drinking episodes and the rate of maintaining abstinence. Studies observed that these changes were associated with the medication in some trials over the typical intermediate follow-up duration of 12 weeks to six months.

A key challenge noted in the research is that the overall effect size data show patterns related to a variability in magnitude of outcomes, which is sometimes described as modest in meta-analyses. The evidence also confirms that results apply only to the populations studied, and findings were mixed across some large trials. Studies also note challenges with patient compliance to the daily oral regimen in real-world settings, which means certainty remains low regarding the assessment of sustained outcomes.

Evidence from Studies for Opioid Use Disorder (OUD)

The role of oral Naltrexone in Opioid Use Disorder (OUD) was observed in individuals who had successfully completed detoxification and were opioid-free. Research explored outcomes related to the maintenance of abstinence. Studies monitored outcomes related to the rate of relapse and retention. The most significant limitation noted is the difficulty patients had with maintaining compliance with the daily medication in clinical practice settings. This means limited comparative evidence is available for long-term sustained abstinence.

Key Studies & References

1. Naltrexone

Common questions about Adepend (FAQ)

---

Q: What is Adepend used for?

Adepend is officially approved for treating alcohol dependence and opioid dependence. It works by blocking the effects of opioids in the brain, and while the precise mechanism for alcohol dependence is not fully understood, regulatory documents confirm its use for both conditions.

---

Q: How long does Adepend typically take to work?

According to official product information, Adepend is rapidly absorbed and starts acting soon after it is taken. However, the full therapeutic benefit is generally realized over time when Adepend is used as part of a comprehensive treatment program, according to regulatory sources.

---

Q: Can I take Adepend with food?

Regulatory documents state that Adepend can be taken with or without food. Taking the medication with a meal, however, may help to minimize certain gastrointestinal side effects, such as stomach upset or nausea, as indicated by official product information.

---

Q: What should I do if I miss a dose of Adepend?

Regulatory documents typically instruct that if a dose is missed, it should be taken as soon as the patient remembers. If it is nearly time for the subsequent dose, the official guidance is to skip the missed dose and resume the normal dosing schedule. Official information specifies that patients must not take two doses at the same time to compensate for the missed dose.

---

Q: Does Adepend contain opioids or narcotics?

No, Adepend does not contain any opioids or narcotics. The active ingredient in Adepend is naltrexone hydrochloride, which is classified as an opioid antagonist. This means the medicine works by blocking opioid receptors in the body rather than activating them.

---

Q: Is Adepend habit-forming or addictive?

According to official regulatory sources, Adepend is not considered habit-forming or addictive. Its active ingredient, naltrexone, does not produce the euphoric or physical dependence effects associated with controlled substances like opioids. This characteristic supports its use in treatment strategies focused on managing dependence.

---

Q: How should Adepend be stored?

Official product information specifies storing Adepend tablets at a controlled room temperature, typically between 20°C and 25°C (68°F and 77°F). It is important to keep it in a tightly closed container and protect it from excessive heat and moisture, which helps ensure the medication remains stable and effective.

Storage and Protection Requirements

Adepend (Naltrexone Hydrochloride Tablets) must be stored under specific conditions to maintain stability until the expiry date. The medicine must not be stored above 25 C. US regulatory standards for the equivalent tablet formulation permit storage at Controlled Room Temperature (20 C to 25 C).

To ensure proper protection, the tablets must be kept in the original package in order to protect from light. Furthermore, to prevent accidental ingestion, the medication must be stored out of the sight and reach of children.

Classification	Official Regulatory Constraint
Temperature	Do not store above 25 C
Container	Store in the original package

Disposal Instructions

Regulatory documents explicitly state that unused or expired Adepend must not be thrown away via wastewater or standard household waste. Patients are instructed to ask the pharmacist how to throw away medicines no longer needed. If a drug take-back option is unavailable, federal guidelines recommend mixing the tablets with an unappealing substance, such as coffee grounds, and placing the mixture into a sealed container before disposal in the household trash.